Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29

Chemed (NYSE: CHE) will release Q2 2026 results for the quarter ended June 30 on Tuesday, July 28, 2026, after the close, followed by a 10:00 a.m. ET call on July 29. The company will discuss quarterly results and provide a business update via webcast and teleconference, with a replay available shortly after the call. This is a scheduled earnings announcement with no new financial figures or guidance changes reported yet.

Analysis

This is a pure event-calendar setup, not a fundamental signal. CHE typically trades as a quality/defensiveness compounder, so the market rarely pays up for upside unless management can prove hospice census stability and labor-cost discipline; absent that, the risk is a multiple reset rather than a large earnings miss. The immediate move is likely driven more by guidance language than by the quarter itself, because small changes in reimbursement, staffing, or utilization assumptions can shift the stock’s fair multiple faster than the underlying EPS change.

The second-order issue is that Roto-Rooter can cushion hospice weakness, which makes a superficially ‘mixed’ print dangerous for shorts: the stock may not break on headline revenue if the plumbing business offsets a softer VITAS read. The more interesting bearish setup is if hospice margin pressure appears structural rather than transitory, because that would challenge the premium valuation of the entire defensive healthcare-services cohort. A soft print would also matter for hospice-adjacent proxies and suppliers, since investors tend to extrapolate labor and reimbursement pressure across the space.

Contrarian view: consensus often treats CHE as a low-drama compounder, but that can create asymmetric downside if the quarter confirms that predictability is fading. Over 1-3 months, the key catalysts are margin commentary, census trends, and any fiscal-year guide revision; over 6-18 months, the real driver is whether hospice growth can outpace wage inflation. The thesis is falsified if management reaffirms full-year outlook and the next month’s operating data show stable census and normalized labor costs.

Key Decisions for Investors

• No pre-earnings directional trade in CHE; treat this as an event-volatility check. Enter only if 1-week implied move is below the stock’s historical post-earnings realized move; otherwise avoid paying for premium.
• If CHE sells off >5% on a margin/census disappointment but management keeps FY guidance intact, buy the dip for a 1-3 month mean-reversion trade; exit if the next quarterly update confirms persistent hospice margin compression.
• If the print shows hospice labor pressure or reimbursement sensitivity, short CHE on the first gap-up fade with a tight stop above the pre-earnings high; target a 6-10% re-rating lower over 1-2 months as the market de-rates the quality multiple.
• Watch the hospice basket for spillover: a negative VITAS read is a caution signal for ENHAB and other hospice/home-care exposures; use CHE as the cleaner read-through since it is the quality benchmark.
• If options are liquid and implied volatility is cheap versus the last four quarters, consider a delta-neutral post-close straddle into the release; otherwise stay flat and wait for the call transcript.